CTOs on the Move

Synovics Pharmaceuticals

www.synovics.com

 
Synovics Pharmaceuticals, Inc. is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.synovics.com
  • 2425 E Camelback Rd Ste 450
    Phoenix, AZ USA 85016
  • Phone: 602.508.0112

Executives

Name Title Contact Details

Similar Companies

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Apeel Sciences

Apeel Sciences creates products from natural plant extracts that allow growers to reduce reliance on pesticides, increase produce quality, and provide superior shelf life without refrigeration.

Luknova

Luknova is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dermavant

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients` lives. The patient is at the heart of everything we do.